Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Accumulated Depreciation & Amortization (2016 - 2025)

Integra Lifesciences Holdings' Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $444.0 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 11.85% year-over-year to $444.0 million; the TTM value through Dec 2025 reached $444.0 million, up 11.85%, while the annual FY2025 figure was $444.0 million, 11.85% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $444.0 million at Integra Lifesciences Holdings, up from $396.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $444.0 million in Q4 2025 and bottomed at $314.9 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $367.4 million (2023), against an average of $370.6 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization increased 4.72% in 2022 before it rose 11.85% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $314.9 million in 2021, then increased by 4.72% to $329.7 million in 2022, then rose by 11.44% to $367.4 million in 2023, then increased by 8.02% to $396.9 million in 2024, then grew by 11.85% to $444.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Accumulated Depreciation & Amortization are $444.0 million (Q4 2025), $396.9 million (Q4 2024), and $367.4 million (Q4 2023).